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Abstract Chinese painted quails immunized with a single
dose (6 lg HA) of inactivated H5N1 (clade 1) influenza
vaccine NIBRG-14 and challenged with 100 LD50 of the
heterologous A/Swan/Nagybaracska/01/06(H5N1) (clade
2.2) strain were protected, whereas unvaccinated quails
died after challenge. No viral antigens or RNA were
detected in cloacal swabs from immunized animals. Sera
obtained post-immunization gave low titres in serological
assays against the vaccine and the challenge viruses. Our
results demonstrate the protective efficacy of the NIBRG-14
strain against the challenge virus and the usefulness of these
small birds in protection studies of influenza vaccines.
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Highly pathogenic avian influenza virus (HPAI) strains
cause significant mortality in unvaccinated chickens, but
their virulence varies in mammals, and mutations in certain
viral genes coding for structural and non-structural proteins
contribute to virulence [7, 14, 18]. HPAI strains also cause
human infections with high mortality rates, some with a
high probability of human-to-human transmission, and they
are thus a constant threat to humans [27].
When the mammalian virulence of HPAI H5N1 strains,
including human isolates, was tested either in mice or in
ferrets, these strains proved to be highly pathogenic or
caused only mild or no symptoms. Few studies have
measured virulence in both mice and ferrets; some strains
have displayed similar pathogenicity in both animals, but
other HPAI strains have exhibited virulence differences,
especially at high doses [4, 18, 21, 33]. Inbred mouse
strains vary considerably in their ability to resist the H5N1
virus, and the distinct expression profiles of inflammatory
mediators have been suggested to control disease severity
[1]. Such observations indicate that results obtained in
H5N1 mammalian protection models can vary with the
animal species and the dose and type of the experimentally
applied challenge virus.
The immunogenicity and protection-conferring ability
of a candidate vaccine virus, NIBRG-14 (clade 1), have
been evaluated in mammalian model systems. The pro-
tective effect of the anti-haemagglutinin (HA) and anti-
neuraminidase (NA) antibodies in BALB/c mice was
shown by injecting the serum into severe combined
immunodeficiency mice, which were then challenged with
a homologous highly pathogenic H5N1 virus strain [25].
Immunization with the adjuvanted NIBRG-14 vaccine
strain conferred protection in mice or monkeys against a
lethal challenge with homologous or heterologous strains
[9, 10, 22]. In humans, one injection of the NIBRG-14
vaccine triggered antibody responses that cross-reacted
with clade 2 H5N1 strains, including the A/Swan/Nagy-
baracska/01/06(H5N1) reassortant strain, in in vitro sero-
logical assays [6]. These earlier results demonstrated the
cross-clade efficacy of the NIBRG-14 vaccine strain.
Animal model systems that met the requirements of high
susceptibility to a great variety of H5N1 viruses, easy
animal handling, and fast, cost-effective and reliable results
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are still needed. The HPAI H5N1 strains tested so far were
all pathogenic in chickens [8, 17] and Japanese quails
(Coturnix-japonica) [11, 13, 19, 32]. The Chinese painted
quail (Coturnix-chinensis, formerly Excalfactoria chinen-
sis, in the family Phasianidiae of the order Galliformes) is
the smallest ‘‘true quail’’, common worldwide in avicul-
ture; the average weight of the adult male and female is
about 48 and 56 g, respectively. Chinese painted quails are
superior to chickens and Japanese quails due to their ease
of handling and general care, hardiness, excellent repro-
ductive performance, and less expensive maintenance [26].
Importantly, Chinese painted quails are smaller in size than
chickens and Japanese quails. Using Chinese painted quails
for vaccine studies with HPAI H5N1 viruses that require
enhanced biosafety level 3 (BSL-3?) conditions provides a
reasonable opportunity for the inclusion of the birds in
appropriate numbers and groups in the experiments, thus
achieving scientifically acceptable results. Quails carry
sialic acid receptors with the potential of binding of avian
and human influenza viruses, thereby serving as an inter-
mediate host for the zoonotic transmission of influenza
viruses [30] and potentially as a challenge system for
human and avian influenza virus vaccines. We are not
aware of published results on the use of Chinese painted
quails in influenza vaccine research.
We set out to investigate the possible usefulness of the
Chinese painted quail in H5N1 vaccine studies. We dem-
onstrated the high pathogenicity of the wild-type A/Swan/
Nagybaracska/01/06(H5N1) (clade 2.2) strain in Chinese
painted quails and the protective effect of vaccination with
the NIBRG-14 strain (clade 1) against this heterologous
strain, demonstrating for the first time that Chinese painted
quails are useful, reliable, and economically and techni-
cally tractable for measuring the protective effect of vac-
cination against H5N1 viruses.
In our experiments, 10-week-old Chinese painted quails
that were seronegative for currently circulating influenza A
and B viruses (K.A.G. Technologies Ltd, Hungary) were
immunized with the NIBRG-14 H5N1 (clade 1) strain and
challenged with the A/Swan/Nagybaracska/01/06(H5N1)
(clade 2.2) strain at week 3 or 6 after immunization.
The NIBRG-14 virus strain, obtained from the National
Institute for Biological Standards and Control, London,
UK, is a reverse-genetics-derived 2:6 reassortant and one
of the available and proposed candidate A (H5N1) vaccines
[5]. The seed virus was grown in eggs. The formaldehyde-
inactivated whole-virus vaccine, produced by Omninvest
Ltd., Hungary, contained 6 lg HA and 0.3 mg aluminum
phosphate adjuvant/dose. The preparation and immunoge-
nicity of the vaccine in humans were described earlier [6,
28, 29].
The HPAI challenge strain, influenza A/Swan/Nagy-
baracska/01/06(H5N1), a wild-type avian influenza virus,
was isolated in Hungary and shown to belong to clade 2.2
on the basis of HA sequences [6]. The TCID50 of the virus
was determined by titration in Madin-Darby canine kidney
cells. To determine the LD50, birds were inoculated sub-
cutaneously (s.c.) with serial dilutions of the virus in a
volume of 100 ll, 4 birds for each dilution, and monitored
daily for morbidity and mortality for 2 weeks. The TCID50
and LD50 titres were calculated by the method of Reed and
Muench [23] and compared; 50 TCID50 were required to
give one LD50 in Chinese painted quails.
The immunization and challenge experiments were
conducted in the BSL-3? containment facility at the
National Center for Epidemiology, as approved for such
use by the Chief Medical Officer of Hungary. The facility
was secured by procedures recognized as appropriate by
the institutional biosafety officers, facility management and
Laboratory Animal Care Committee as well as Hungarian
government inspectors. The Chinese painted quails were
housed in individually ventilated cages used convention-
ally for mouse experiments (4 birds/cage).
In the first experimental series, 12 birds were immu-
nized s.c. twice at an interval of 3 weeks with the NIBRG-
14 strain in a volume of 100 ll and challenged s.c. in 3
groups of 4 animals at week 6 with 1 or 10 LD50 of the
A/Swan/Nagybaracska/01/06(H5N1) virus in a volume of
100 ll. Three of the 4 unimmunized control birds that
received 1 LD50 and all four of the unimmunized animals
that received 10 LD50 of the challenge virus died within
8 days post-challenge. All of the immunized birds survived
and remained healthy, demonstrating the protective effect
of the twice-inoculated vaccine virus.
In the second experimental series, 24 birds were
immunized with a single dose of the vaccine strain. Three
weeks later, 8 birds were bled for serologic testing, and 16,
in 2 groups of 8 animals, were challenged with 10 or 100
LD50 of strain A/Swan/Nagybaracska/01/06(H5N1). Six-
teen unimmunized quails, 8 per group, served as controls
and were challenged similarly. All birds in the unvacci-
nated control groups died within 8 days post-challenge,
while all vaccinated quails remained healthy and showed
no clinical signs of illness (Fig. 1). The unvaccinated group
challenged with the 10 or 100 LD50 dose displayed
depression, reluctance, decreases in food and water con-
sumption, and increased respiratory rates at 24 h post-
challenge. At 48 h and 96 h, the clinical signs were similar,
but the weakness and drowsiness were more pronounced,
and diarrhoea occurred.
Cloacal swab samples from immunized and unimmu-
nized animals were analysed for the presence of viral
antigens and RNA. The RapidSignalTM Influenza H5
Dipstrip (Orgenics Ltd., Israel) chromatographic immuno-
assay was used to detect H5 virus antigens according to the
instructions of the manufacturer. RNA was extracted with
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Tri-Reagent (Sigma-Aldrich, St. Louis, MO, USA), and
reverse transcription was performed with avian transcrip-
tase according to the manufacturer’s instructions (Applied
Biosystems Foster City, CA, USA). REDTaq ReadyMix
PCR Reaction Mix with MgCl2 (Sigma-Aldrich) was used
in the PCR with a primer pair corresponding to the M
segment; positive results were confirmed with specific H5
primers [31]. The results showed that H5 viral antigens
were present in the cloacal swabs of all the unvaccinated
control birds. Those unvaccinated and challenged with 100
LD50 were PCR positive, demonstrating the presence of
viral RNA in the samples. All samples obtained from
immunized and challenged animals were negative for H5
viral antigens and RNA (Table 1). Oropharingeal swabs
were not taken from the birds for analysis of viral antigens
and RNA.
Sera from 8 birds at 3 weeks after single-dose immu-
nization were tested for anti-HA and neutralization anti-
bodies against the vaccine and challenge strains.
Haemagglutination inhibition (HI) tests were performed by
standard procedures with chicken red blood cells and 4 HA
units of virus/well [16]. The microneutralization (MN)
assay was performed as described [31]. Positive antibody
controls for HI and MN assays were prepared by immu-
nization of birds with s.c. injection of an emulsion con-
taining 0.5 mg of whole, formaldehyde-inactivated
influenza NIBRG-14 four times with complete or incom-
plete Freund’s adjuvant (Calbiochem, La Jolla, CA, USA).
The titre of the positive antibodies against the NIBRG-14
strain was [1:40 in the HI and MN assays. Sera obtained
from non-immunized birds did not react in these assays.
Statistical analysis was performed with the SPSS program,
version 17.0. Differences between groups in continuous
variables were calculated using the nonparametric Mann-
Whitney U-test; p \ 0.05 was taken as significant.
All birds responded with an HI titre of 10.6-32, geo-
metric mean titre (GMT) of 21.1 against the NIBRG-14
homologous strain, but the HI titres against the A/Swan/
Nagybaracska/01/06(H5N1) strain were significantly
lower, some \ 1:4 (GMT = 4.4). When the same sera
were examined by MN, the animals gave a GMT of 20.7
against the vaccine strain, and the five animals that
exhibited seroconversion against the A/Swan/Nagy-
baracska/01/06(H5N1) strain in the HI test were also
positive in the MN assay. The sera from three birds with a
titre of \ 1:4 against the challenge virus in the HI tests
showed similarly undetectable titres in the MN assays
(Table 2). Positive control antibodies exhibited the
expected HI and MN titres against the NIBRG-14 strain;
negative antibody controls did not react in the assays (not
shown).
Correlates for protection from disease and death by
H5N1 isolates are complex. HI titres of C 1:40 in [70 %
Fig. 1 Protection of Chinese painted quails immunized with the
NIBRG-14 (clade 1) vaccine against the highly pathogenic heterol-
ogous A/Swan/Nagybaracska/01/06(H5N1) (clade 2.2) strain. Sixteen
birds vaccinated s.c. with a single dose of NIBRG-14 vaccine (6 HA/
dose) were challenged in two groups of eight birds with 10 or 100
times the LD50 of the A/Swan/Nagybaracska/01/06(H5N1) strain at
3 weeks post-immunization. Sixteen unvaccinated birds were simi-
larly challenged. Mortality was monitored on a daily basis for 14 days
Table 1 Protection from virus excretion in the intestinal tract after challenge of Chinese painted quails immunized with a single dose of the
NIBRG-14 strain
Quails challenged with A/Swan/
Nagybaracska/01/06(H5N1)
Viral antigens no. of ? samples/total
no of samples/no. of quails
Viral RNA no. of ? samples/total
no. of samples/no. of quails
Immunized and challenged with 100 LD50 0/40/8 0/40/8
Immunized and challenged with 10 LD50 0/40/8 0/40/8
Non-immunized and challenged with 100 LD50 14/14/6 14/14/6
Non-immunized and challenged with 10 LD50 16/16/7 ND
Quails were immunized with a single dose of the NIBRG-14 vaccine and challenged with the A/Swan/Nagybaracska/01/06(H5N1) strain.
Cloacal swab samples were collected on days 0, 2, 4, 6, 8 and 10, but samples were not taken from dead animals. Thirty-two samples from the
four groups obtained on day 0 were all negative for viral antigen and RNA (not shown). Results obtained from samples collected on days 2–10
are included in the table
ND not done
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of adult subjects are required for the licensing of currently
available influenza vaccines [3]. Our results, confirming
earlier results [2, 20, 25], suggest that these requirements
may not be critical for avian H5N1 viruses and indicate that
the low levels or insufficient detection of anti-HA anti-
bodies following immunization with the NIBRG-14 vac-
cine are not limited to mammals, but are also observed with
Chinese painted quail, an avian species that is highly sus-
ceptible to a HPAI H5N1 strain. Protection from a lethal
viral challenge may possibly be independent of the pre-
challenge anti-HA antibody levels, and other mechanisms,
such as anti-NA antibodies, are involved in protection [24,
25]. Alternatively, anti-HA antibodies were present at a
seroprotective level in the sera, but the HI and MN assays
detected avian H5N1 antibody with low sensitivity, as
suggested earlier [20, 25]. Similarly to our results, cross-
reacting antibodies against A/Swan/Nagybaracska/01/
06(H5N1) were detected in in vitro assays in only about
25 % of humans who were reactive to the homologous
NIBRG-1 strain [6]. Furthermore, the vaccine and chal-
lenge viruses possessed antigenically distinct HA and NA
genes from the clade 1 A/Vietnam/1194/2004 and clade 2
A/Swan/Nagybaracska/01/06(H5N1) strains, respectively,
but the cell-mediated immune responses directed to the
internal proteins of the strains, or to common cytotoxic T
cell epitopes in the vaccine and challenge HA, may con-
tribute to or be responsible for the cross-clade protection.
Antibody-dependent cellular cytotoxicity was detected in
humans in the absence of neutralization to various strains,
including a H5N1 HA [12]. New approaches using
recombinant technologies to identify universal influenza
vaccines that improve the level of cross-protection are
being investigated [15].
The limitations of our study include the lack of inves-
tigations on the mechanism of protection in the presence of
low or undetectable levels of anti-HA antibodies against
the challenge virus. Moreover, some wild-type H5N1 iso-
lates may be more pathogenic in quails than the A/Swan/
Nagybaracska/01/06(H5N1) challenge virus, hence requir-
ing higher levels of immune responses for protection.
Aspects of these limitations demand further studies.
In summary, we report that (1) small Chinese painted
quails may serve for testing vaccine-induced protection
against avian H5N1 virus strains, and (2) a single dose of
NIBRG-14 vaccine containing 6 lg HA induces anti-HA
and neutralizing antibodies at low titres against the
homologous strain in all quails and seroconversion against
the heterologous strain in only some of the quails, but it
confers 100 % protection in those challenged with high
doses of the highly pathogenic heterologous (clade 2) strain
A/Swan/Nagybaracska/01/06(H5N1). Thus, the conven-
tionally used anti-HA titer might not be a good indicator
for protection against influenza A (H5N1) virus.
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